Results 111 to 120 of about 1,721 (143)

The Effect of Vericiguat on Endothelial Function in Patients With Heart Failure With Reduced Ejection Fraction: A Pilot Randomized Study. [PDF]

Am J Cardiol
Sideris K, Bunsawat K, Brinker L, Braun E, Iacovelli J, Chen A, Simmons JM, Zhao J, Carter S, Tseliou E, Kyriakopoulos CP, Hanff TC, Florido R, Brann AM, Fang JC, Greene T, Wray DW, Stehlik J.   +17 more
europepmc   +1 more source

Vericiguat Alleviates Atrial Electrical and Structural Remodeling in Rats with Atrial Fibrillation. [PDF]

Anatol J Cardiol
Zhang X, Wang Y, Shen L, Shuai Z, Liu W, Wen Q, Tang H, Chen Y, Yang Y, Li H.   +9 more
europepmc   +1 more source

Effects of Sacubitril Valsartan Combined With Vericiguat on NT-proBNP and CK-MB Levels in Patients With Chronic Heart Failure. [PDF]

J Appl Toxicol
Jin L, Yang T.
europepmc   +1 more source

Vericiguat in heart failure with reduced ejection fraction: not vanity, but vindication. [PDF]

ESC Heart Fail
Ambrosy AP.
europepmc   +1 more source

Association of Vericiguat with Improvement in Functional Abilities and Comprehensive Geriatric Assessment in Elderly Patients with Worsening Heart Failure. [PDF]

Pharmaceuticals (Basel)
Armentaro G, Scarcelli MR, Severini G, Pastura CA, Cassano V, Maruca F, Marincola LF, Cortese G, Condoleo V, Miceli S, Maio R, Volterrani M, Vitale C, Rosano GMC, Sciacqua A.   +14 more
europepmc   +1 more source

Vericiguat and mortality in heart failure and reduced ejection fraction: the VICTOR trial. [PDF]

Eur Heart J
Butler J, Fioretti F, McMullan CJ, Anstrom KJ, Barash I, Bonaca MP, Borentain M, Corda S, Teixeira PP, Ezekowitz JA, Gates D, Lam CSP, Lewis EF, Lindenfeld J, Mentz RJ, O'Connor CM, Ponikowski P, Reddy YNV, Rosano GMC, Saldarriaga C, Senni M, Udelson J, Urbinati A, Vlajnic V, Voors AA, Xing A, Patel MJ, Zannad F.   +27 more
europepmc   +1 more source

Editorial: New frontiers in heart failure therapy: mechanisms, efficacy, and challenges. [PDF]

Front Cardiovasc Med
Cheng TH, Wang Y, Vassilev D.
europepmc   +1 more source

Landmark clinical trials shaping contemporary guideline-directed medical therapy for heart failure. [PDF]

ESC Heart Fail
Tkaczyszyn M, Kapłon-Cieślicka A, Janiszewski M, Klimczak-Tomaniak D, Jędrzejczyk-Patej E, Burchardt P, Abdin A, Böhm M, Chioncel O, Baudry G, Cobo Marcos M, Zymliński R, Núñez J, Metra M, Ponikowski P.   +14 more
europepmc   +1 more source

Low-Dose Vericiguat in Heart Failure With Reduced Ejection Fraction: A Case Report. [PDF]

Cureus
Orji C.
europepmc   +1 more source

Differential cardiovascular benefits of SGLT2 inhibitors, sacubitril/valsartan, omecamtiv mecarbil, and vericiguat across heart failure phenotypes: a systematic review and meta-analysis. [PDF]

Front Pharmacol
Wang M, Zuo Z, Wu T, Zhou Z.
europepmc   +1 more source